Long-axis view on TEE. PML = posterior mitral leaflet, AML = anterior mitral leaflet (Photo Credit: Hannes Alessandrini) As MitraClip procedures continue to expand as an option for nonsurgical ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter mitral valve repair improved clinical outcomes in patients with HF across all quartiles of mitral ...

Surgical repair decreased MR more than MitraClip ®. In 12-month follow-up, 20% of MitraClip patients required surgery for mitral dysfunction versus 2% in surgical patients. Both groups had ...

The US Food and Drug Administration (FDA) has expanded the indication for the MitraClip (Abbott) device to include patients with normal mitral valves who develop symptoms of heart failure and moderate ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in ...

SAN DIEGO (March 15, 2015) --The commercial track record with transcatheter mitral valve repair, approved for patients at high risk for surgery, compares favorably with pre-approval reports, according ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- ...

Abbott Laboratories (NYSE: ABT) has scored a fresh victory across the Atlantic Ocean. The company announced Monday that it has been granted a CE Mark for its MitraClip G4, the latest version of its ...

In 2013, the FDA approved an implantable device to treat leaky heart valves. Among its inventors was Mehmet Oz, the former television personality and former U.S. Senate candidate widely known as "Dr.

Cardiomech AS raised $13 million in fresh capital via a convertible loan agreement that will go towards developing its transcatheter mitral valve chordal repair technology. The round was heavily ...

Versions of the device have been available in the EU since 2008. The G4 had already been approved for use in the U.S. by the Food and Drug Administration. It treats mitral regurgitation, a condition ...